Back to Search
Start Over
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
- Source :
-
Journal for immunotherapy of cancer [J Immunother Cancer] 2018 Dec 04; Vol. 6 (1), pp. 137. Date of Electronic Publication: 2018 Dec 04. - Publication Year :
- 2018
-
Abstract
- Chimeric Antigen Receptor (CAR) T cell therapies - adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals. Based on the promise generated from these successes, the field is rapidly evolving to include new disease indications and CAR designs, while simultaneously reviewing and optimizing toxicity and management protocols. As such, this review provides expert perspective on the significance and clinical considerations of CAR T cell therapies in order to provide timely information to clinicians about this revolutionary new therapeutic class.
- Subjects :
- Animals
Antigens, Neoplasm immunology
Clinical Trials as Topic
Genetic Engineering
Hematologic Neoplasms diagnosis
Humans
Receptors, Antigen, T-Cell genetics
Receptors, Chimeric Antigen genetics
Treatment Outcome
Hematologic Neoplasms immunology
Hematologic Neoplasms therapy
Immunotherapy, Adoptive adverse effects
Immunotherapy, Adoptive methods
Receptors, Antigen, T-Cell metabolism
Receptors, Chimeric Antigen metabolism
T-Lymphocytes immunology
T-Lymphocytes metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 2051-1426
- Volume :
- 6
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal for immunotherapy of cancer
- Publication Type :
- Academic Journal
- Accession number :
- 30514386
- Full Text :
- https://doi.org/10.1186/s40425-018-0460-5